X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GSK PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GSK PHARMA SANOFI INDIA/
GSK PHARMA
 
P/E (TTM) x 39.5 68.0 58.1% View Chart
P/BV x 8.5 13.7 62.3% View Chart
Dividend Yield % 1.1 2.1 50.2%  

Financials

 SANOFI INDIA   GSK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
GSK PHARMA
Mar-18
SANOFI INDIA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5602,760 165.2%   
Low Rs4,4002,040 215.7%   
Sales per share (Unadj.) Rs1,028.5339.0 303.4%  
Earnings per share (Unadj.) Rs129.041.4 311.4%  
Cash flow per share (Unadj.) Rs186.045.9 405.1%  
Dividends per share (Unadj.) Rs68.0035.00 194.3%  
Dividend yield (eoy) %1.51.5 104.1%  
Book value per share (Unadj.) Rs753.6242.9 310.3%  
Shares outstanding (eoy) m23.0384.70 27.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.47.1 61.5%   
Avg P/E ratio x34.757.9 59.9%  
P/CF ratio (eoy) x24.152.3 46.1%  
Price / Book Value ratio x5.99.9 60.2%  
Dividend payout %52.784.5 62.4%   
Avg Mkt Cap Rs m103,174203,280 50.8%   
No. of employees `0003.6NA-   
Total wages/salary Rs m3,5925,234 68.6%   
Avg. sales/employee Rs Th6,537.7NM-  
Avg. wages/employee Rs Th991.4NM-  
Avg. net profit/employee Rs Th819.8NM-  
INCOME DATA
Net Sales Rs m23,68628,715 82.5%  
Other income Rs m708545 129.8%   
Total revenues Rs m24,39429,260 83.4%   
Gross profit Rs m5,2815,059 104.4%  
Depreciation Rs m1,313380 345.5%   
Interest Rs m152 750.0%   
Profit before tax Rs m4,6615,222 89.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m1,6911,892 89.4%   
Profit after tax Rs m2,9703,508 84.7%  
Gross profit margin %22.317.6 126.6%  
Effective tax rate %36.336.2 100.1%   
Net profit margin %12.512.2 102.6%  
BALANCE SHEET DATA
Current assets Rs m15,67321,815 71.8%   
Current liabilities Rs m6,67815,999 41.7%   
Net working cap to sales %38.020.3 187.5%  
Current ratio x2.31.4 172.1%  
Inventory Days Days7664 119.5%  
Debtors Days Days2219 119.4%  
Net fixed assets Rs m8,09812,475 64.9%   
Share capital Rs m230847 27.2%   
"Free" reserves Rs m17,08819,726 86.6%   
Net worth Rs m17,35620,573 84.4%   
Long term debt Rs m06 0.0%   
Total assets Rs m25,40039,475 64.3%  
Interest coverage x311.72,612.0 11.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.7 128.2%   
Return on assets %11.88.9 132.2%  
Return on equity %17.117.1 100.4%  
Return on capital %26.926.2 102.6%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,145564 1,266.8%   
Fx outflow Rs m6,8467,429 92.2%   
Net fx Rs m299-6,865 -4.4%   
CASH FLOW
From Operations Rs m3,2264,728 68.2%  
From Investments Rs m-1,555-1,042 149.2%  
From Financial Activity Rs m-1,818-3,066 59.3%  
Net Cashflow Rs m-147620 -23.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 50.7 119.1%  
Indian inst/Mut Fund % 14.4 10.2 141.2%  
FIIs % 14.6 23.8 61.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 15.4 68.2%  
Shareholders   15,184 102,036 14.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 18, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - UNICHEM LAB COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS